

Prostate cancer: diagnosis and management Advisory Committee Interests Register

Register last updated: 28/09/21

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Ann Hoskins	Chair	Non-financial professional and personal interests	Advocate / member of the British Association of Child and Adolescent PH.		Apr 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Direct financial	Private practice, mirrors NHS practice This includes plain film, CT, US and MRI reporting sessions and urology MDT and clinico-radiology meetings. Patients tend to be relatively stable, with out-patient led, routine investigations in private practice. On the radiology on-call consultant rota for body imaging.	May 2017	May 2021	Ongoing	Declare and participate. Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Prostate Cancer UK, research advisory committee member.	Oct 2016	May 2021	Ongoing	Declare and participate. Rationale: Not scheduled to sit on any grant call committees at present, no

							control in regard to the grants to be reviewed.
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Member National Cancer Research Institute Prostate Clinical Studies Group.	Sep 2015	May 2021	June 2021	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	British Society of Urogenital Radiology, management committee member.	Mar 2017	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Independent International Expert Clinical Reviewer for National Cancer Control Programme, Evidence-Based Cancer Guideline in Ireland.	Oct 2020	May 2021	Jan 2021	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	European Society of Urogenital Radiology, prostate working Group member (radiology MRI focused).	Feb 2015	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	European Society of Urogenital Radiology, Prostate-Pathways subgroup, Vice-chair.	Feb 2015	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline

Tristan Barrett	Uroradiologist	Indirect financial	Close family member employed as Research Scientist, Drug Discovery at Astra Zeneca.	Apr 2019	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Clinical Radiology editorial board member.	2017	Jul 2021	Ongoing	Declare and participate. Rationale: No control over the papers allocated, mostly imaging-based
Tristan Barrett	Uroradiologist	Indirect financial	Principle Investigator, Research dynamic predictive model for baseline early detection and follow-up re-evaluation of the risk of prostate cancer progression on active surveillance (PROGRESS Prostate) Funded CRUK International Alliance for Cancer Early Detection (ACED).	2020	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Co-author, The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T1 relaxometry in patients	Nov 2020	Jul 2021	Nov 2020	Declare and participate. Rationale: Not specific to the update of the guideline

			with prostate cancer. Scientific Reports journal.				
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Co-author, MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. BJU International.	Nov 2020	Jul 2021	Nov 2020	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Co-author, ESUR/ESUI Consensus Statements on Multi-parametric MRI for the Detection of Clinically Significant Prostate Cancer: Quality Requirements for Image Acquisition, Interpretation and Radiologists' Training. European Radiology.	May 2020	Jul 2021	May 2020	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Co-author, NPV of multi-parametric MRI in detection of clinically significant prostate cancer in the PI-RADS era: a systematic review and meta-analysis. European Urology.	May 2020	Jul 2021	May 2020	Declare and participate. Rationale: Not specific to the update of the guideline

Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	NICE committee member Transperineal biopsy in people with suspected prostate cancer.	Apr 2021	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Quality checkpoints in magnetic resonance imaging - Royal Society of Medicine: Radiology Section's Imaging and prostate cancer: Diagnosis, treatment and monitoring webinar.	2021	Jul 2021	2021	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	Speaker at the UK Imaging & OncologyCongress, 2021 High risk patient with potential curative intent - should we be doing more?	Jun 2021	Jul 2021	Jun 2021	Declare and participate. Rationale: Presentation covered current guidance using case examples
Tristan Barrett	Uroradiologist	Non-financial professional and personal interests	International Cancer Imaging Society (ICIS) - Masterclass in Imaging of Prostate Cancer (basic MRI interpretation).	Feb 2021	Jul 2021	Feb 2021	Declare and participate. Rationale: Not specific to the update of the guideline
Guy Chetiyawardana	Co-opted Therapeutic radiographer	Non-financial professional and personal interests	Speaker at prostate cancer support groups on radiotherapy process and side effects, and advocating for patient voices in improving care.	2015	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline

Guy Chetiyawardana	Co-opted Therapeutic radiographer	Non-financial professional and personal interests	Co-chair for Society of Radiographers prostate special interest group.	2017	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Guy Chetiyawardana	Co-opted Therapeutic radiographer	Direct financial	NIHR pre-doctoral award fellow- professional support and funding to support entry into doctoral level study.	2020	Jul 2021	2021	Declare and participate. Rationale: Not specific to the update of the guideline
Steve Hazell	Histopathologist	Direct financial	Royal Marsden, private practice, mirrors NHS work.	2011	May 2021	Ongoing	Declare and participate. Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully
Steve Hazell	Histopathologist	Non-financial professional and personal interests	Involved in the PROFILE Prostate cancer Trials at Royal Marsden / ICR. The study is looking at how patients with a strong family history of prostate	2011	July 2021	Ongoing	Declare and participate. Rationale: Involvement with the trials is limited to assessing the prostate biopsies histopathology.

			cancer are diagnosed / managed.				
Steve Hazell	Histopathologist	Non-financial professional and personal interests	Involved in and BARCODE1 Prostate cancer Trials at Royal Marsden / ICR. The study is looking at genetic screening of asymptomatic patients aged 50 to 69 to place individuals into risk levels of prostate cancer.	2018	July 2021	Ongoing	Declare and participate. Rationale: Involvement with the trials is limited to assessing the prostate biopsies histopathology.
Steve Hazell	Histopathologist	Non-financial professional and personal interests	Involved in the analysis of TRACERx Renal Consortium data at Royal Marsden. The study is related to renal cell carcinoma.	2017	July 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Steve Hazell	Histopathologist	Non-financial professional and personal interests	Co-author- Detection and staging of radio-recurrent prostate cancer using multiparametric Journal of Radiology.	Apr 2021	July 2021	Apr 2021	Declare and participate. Rationale: Not specific to the update of the guideline
Steve Hazell	Histopathologist	Non-financial professional and personal interests	Co-author Pan-cancer analysis of whole genomes.	2020	July 2021	2020	Declare and participate. Rationale: Not specific to the update of the guideline

Steve Hazell	Histopathologist	Non-financial professional and personal interests	Co-author Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of TMPRSS2-ERG Translocation With SOX2 Amplification. JCO Journal Oncology Practice.	Oct 2020	Oct 2020	2020	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Direct financial	NICE Covid-19 rapid guideline on elective surgery guideline committee lay member, payment received.	June 2021	July 2021	July 2021	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Direct financial	Lay Representative Health Education England North-East, payment received	2019	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Direct financial	Lay Committee Member on the General Pharmaceutical Council, payment received	2016	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Direct financial	Lay Partner Health and Care Professions Council, payment received.	2014	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline

Sheba Joseph	Lay member	Non-financial professional and personal interests	Royal College of Obstetrics and Gynaecology, Lay Examiner.	2018	May 2021	2021	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Direct financial	NICE Perioperative care in adults guideline committee lay member, payment received.	Feb 2018	Jul 2021	Aug 2020	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Direct financial	NHS England & NHS Improvement, Patient and Public Voice Partner, Pastoral, Spiritual and Religious Support (Chaplaincy) Guidelines Steering Group. Payment received.	Sept 2021	Sept 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Indirect financial	Fundraising for Prostate Cancer UK.	2010	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	Awareness talks for Prostate Cancer UK, (travel and subsistence only).	2010	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	Patient involvement to Prostate Cancer Research Group at Surrey University, (travel and subsistence only).	2010	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline

John Marshall	Lay member	Direct financial	Patient involvement to Prostate Cancer Research Group at UCL, University, (travel and subsistence only).	2019	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	Patient involvement to Prostate Cancer Research Group at Newcastle University, (travel and subsistence only).	2016	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	Prostate Cancer Research advisory panel Cancer Research Advisory committee, (honarium paid on occasion, travel and subsistence only).	Jul 2021	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	Prostate Cancer Research North West Cancers Research Advisory committee, (honarium paid on occasion, travel and subsistence only).	2015	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	Lay member of Lancaster University Medical Schools, Learning and Teaching Committee (honarium and expenses).	2016	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline

John Marshall	Lay member	Direct financial	Lay member of Lancaster University Medical Schools, student selection committee (honorary and expenses).	2016	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	Lancaster University Medical Schools, lay interviewer of prospective medical students (honorary and expenses).	2014	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	Lay member of Lancaster University Medical Schools, Sponsorship Committee (honorary and expenses).	2014	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay member	Direct financial	NHS Cancer Programme volunteer, (travel and subsistence only).	Oct 2019	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	GP	Direct financial	Associate Editor of the British Journal of General Practice – reviewing manuscripts submitted for peer review publication in the BJGP, including those relating to cancer.	Oct 2020	May 2021	Ongoing	Declare and participate Rationale: Articles published covering a breadth of topics including prostate cancer
Samuel Merriel	GP	Non-financial professional and	Study advisory group member for 'Diagnostic Journeys in Prostate	Feb 2018	May 2021	Ongoing	Declare and participate.

		personal interests	Cancer' study. (Funded by Cancer Research Wales).				Rationale: Not specific to the update of the guideline
Samuel Merriel	GP	Non-financial professional and personal interests	Data Monitoring Committee member of FINESSE (Finasteride Evaluation in Surveillance for Prostate cancer) Trial (Funded by Yorkshire Cancer Research).	Dec 2020	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	GP	Non-financial professional and personal interests	Senior Editorial Board Member of BMC Cancer – reviewing manuscripts submitted for peer review publication in BM Cancer.	Sep 2020	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	GP	Indirect financial	Doctoral fellowship funded by a Cancer Research UK Catalyst Award (The CanTest Collaborative).	Aug 2018	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	GP	Non-financial professional and personal interests	Lead author; Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors associated with prostate cancer progression using routine primary care data. British Medical Journal.	Feb 2021	Jul 2021	Feb 2021	Declare and participate. Rationale: Not specific to the update of the guideline

Samuel Merriel	GP	Non-financial professional and personal interests	Lead author; A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for Active Surveillance. BMC Urology.	Feb 2021	Jul 2021	Feb 2021	Declare and participate. Rationale: Not identified as part of the evidence base
Samuel Merriel	GP	Indirect financial	Early Detection and Diagnosis Project Award, from Cancer Research UK. Evaluating ethnic differences in blood markers of cancer in primary care.	May 2021	Jul 2021	Ongoing	Declare and participate. Rationale: Not identified as part of the evidence base
Krishna Narahari	Consultant Urologist/Urological Surgeon	Direct financial	Private Medical Practice at Spire Cardiff Hospital in Urology.	2015	May 2021	Ongoing	Declare and participate. Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully

Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Chair, British Association of Urological Surgeons Oncology.	Jan 2021	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Secretary, British Association of Urological Surgeons Oncology.	Jan 2018	May 2021	Dec 2020	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Investigator add Aspirin,- Aspirin vs placebo in cancer recurrence.		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Principal investigator/co-Principal investigator UK Genetic Prostate Cancer Study- Hereditary prostate cancer study.		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Investigator ARAMIS, - commercial trial in advanced prostate cancer.		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Principal investigator/co-Principal investigator ARAMIS Roll over-commercial trial in advanced prostate cancer		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Principal investigator/co-Principal investigator TRANSLATE- trial in set up phase.	2021	May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline

Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	investigator Urinary Biomarkers, trial in early prostate cancer.		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Principal investigator/co-Principal investigator TERRAIN- commercial trial in advanced prostate Cancer.		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Principal investigator/co-Principal investigator TERRAIN extension- Commercial Trial in advanced prostate cancer.		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Indirect financial	The organisation's research and development unit has received clinical trial funding from the following organisations Medical Research Council, National Institute for Health Research. Charities such as; The Urology Foundation ,Prostate Cancer UK, Movember foundation.		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline Committee member has no influence over R&D funding and is not directly supported through R&D funding.
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	National Prostate Cancer Audit, Clinical Reference group and Project Group.	2018	May 2021	Ongoing	Declare and participate.

							Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urologist/Urological Surgeon	Non-financial professional and personal interests	Committee member Prostate Cancer Risk Management Programme guidance on PSA testing.	Mar 2021	Sept 2021	Ongoing	Declare and participate. Rationale: The PCRMG reviews and makes recommendations on PSA testing in non-symptomatic men which is outside the scope of this update.
Brian Shine	Chemical Pathologist Co-opted committee member	Non-financial professional and personal interests	Research group investigating the variability of PSA, and relevance to the risk of developing metastatic prostate cancer. Currently seeking research funding through the NIH in the US.	2021	July 2021	Ongoing	Declare and participate. Rationale: Not identified as part of the evidence base
Santhanam Sundar	Consultant in Clinical Oncology	Direct financial	Private practice mirrors NHS work, self employed, based at the following locations; BMI Park Hospital Nottingham, Genesis care Nottingham, and Spire Hospital Nottingham.	Sept	May 2021	Ongoing	Declare and participate. Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the

							individual can continue to participate fully
Santhanam Sundar	Consultant in Clinical Oncology	Direct financial	Conference ASCO 2021 meeting. (International meeting for all cancers). Registration fee Sponsorship from BAYER.	May 2021	May 2021	May 2021	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology	Direct financial	Advisory boards BAYER, Bayer virtual round table meeting; TOPIC- Castration refractory non-metastatic prostate cancer.	Feb 2021	May 2021	Feb 2021	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology	Direct financial	Payments for speaking engagement/ advisory boards from BAYER. One meeting UK wide webinar; TOPIC- Castration refractory non-metastatic prostate cancer.	Jan 2021	May 2021	Jan 2021	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology	Non-financial professional and personal interests	Member of NHS England Specialised Urology CRG.		May 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology	Non-financial professional and personal interests	Member of Cancer-Research-UK sponsored National SACT Steering.	Nov 2017	May 2021	Jan 2021	Declare and participate. Rationale: Not specific to the update of the guideline

Santhanam Sundar	Consultant in Clinical Oncology	Non-financial professional and personal interests	UK chief investigator EORTC PEACE III trial in prostate Cancer.	2019	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology	Non-financial professional and personal interests	UK chief investigator EORTC PEGASUS trial in prostate Cancer.	2017	July 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology	Non-financial professional and personal interests	Co-author, Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. European Urology.	Aug 2020	Jul 2021	Aug 2020	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology	Non-financial professional and personal interests	Co-author, Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). Journal of Clinical Oncology.	Dec 2020	Jul 2021	Dec 2020	Declare and participate. Rationale: Not specific to the update of the guideline

Joanne Wortley	Specialist Nurse in Urology/Oncology	Indirect financial	Trustee – Registered Charity Prostaïd.	May 2020	Jul 2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
----------------	--------------------------------------	--------------------	--	----------	----------	---------	--

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.